Antibiotics Market Synopsis
Antibiotics Market Size Was Valued at USD 50.8 Billion in 2023, and is Projected to Reach USD 72.9 Billion by 2032, Growing at a CAGR of 4.1% From 2024-2032.
The antibiotics market is defined as the worldwide demand for medicines intended to combat bacterial infections and either eliminate them or prevent their development. Antibiotics are important in managing most infections such as respiratory, urinary, skin, and gastrointestinal infections to mention but a few. The market included branded and generic antibiotics of penicillin, cephalosporin, macrolides, and tetracyclines therapeutic classes. The global need for better antibiotic treatment reaches higher levels when bacterial infections increase, and healthcare facilities improve concurrently.
- The overall demand of antibiotics in the global market has risen from year to year due to the growing rates of bacterial infections, the increasing number of the ageing population, and the demand for better efficacy treatments. With the general enhancement of healthcare related infrastructures in the world more so in the developing countries, the use of antibiotics has grown. Antibiotics are considered effective in treating small infections that if left uncontrolled can cause serious situations. As far as the research and development are concerned, new products have also been developed that signify more efficiency than the older antibiotics and are targeting antibiotic resistant bacteria, a global problem.
- The current antibiotics market offers a greater number of companies which key is attending both the branded and the generics. Despite the fact that antibiotics have been very important to public health, antibiotics resistance is a problem to the market. People have been advised to use antibiotics properly and responsibly which has caused government health to put up rules regarding the use of antibiotics. Nonetheless, due to various regulatory issues, the market is anticipated to grow further through research, development, and growing awareness of bacterial infection, and the availability of specific or resistance-focused antibiotics.
Antibiotics Market Trend Analysis
Rising Focus on Antibiotic Resistance
- Antibiotic resistance is among the most influential trends observed in the antibiotics market in recent years. Thus, due to the use of antibiotics itself, misuse and overuse of antibiotics have made bacteria develop a resistance to path ways of traditional antibiotic therapies. It has therefore led to more funds being sunk into looking for new antibiotics that can deal with this resistance. Further, the pharmaceutical companies are in the process of developing the antibiotics: bacteriophage therapy and antimicrobial peptides. International organizations, such as WHO is also undertaking policies to control the misuse of antibiotics and encourage technological advancement in these”.
Growing Demand in Emerging Economies
- The awareness related to healthcare in the emerging economies of the world has developed at a high pace that has created the biggest opportunity for the antibiotics market. Southeast Asian, Latin American, African and many other Asian nations are developing fast, their medical facilities are improving and they are spending more on healthcare and hence demanding more antibiotics. Infectious diseases have been on the rise in these regions and increased uptake of health care has helped in driving the market. In addition, there is a growing focus of governments in these regions on local production of pharmaceutical products, as well as on the support of regional antibiotic markets. With this increasing demand and the current call for local production and processing of goods, there is great potential for both domestic and foreign pharmaceutical manufacturers.
Antibiotics Market Segment Analysis:
Antibiotics Market is segmented on the basis of Drug Class, Type and Action Mechanism.
By Drug Class, Cephalosporin segment is expected to dominate the market during the forecast period
- The antibiotics market segmented by drug class: The cephalosporin segment accounts for a major market share in the antibiotics market during the forecast period. Fluorquinolones are an additional category of antibiotics that is used for infections including pneumonia, bronchitis and acute bacterial infections of the urinary tracts. This is so because they are reliably effective in eradicating many bacterial infections ranging from ordinary ones to the resistant strains. And, since cephalosporins are approved as first-line therapies for numerous infections, their overall consumption is set to increase even more. The seeming improvement of cephalosporin drug formulations, including the extended-spectrum has boosted the effectiveness of the drug, hence its market dominance. Due to the on-going emergence of antibiotic-resistant bacteria, the cephalosporin class is likely to remain a significant part of the treatment.
By Type, Branded Antibiotics segment expected to held the largest share
- Based on type, it has been identified that the branded antibiotics segment is expected to account for the largest market share of the antibiotics market. Branded antibiotics have their prestige especially concerning efficiency, quality, and the reliability of the Medication brand. These antibiotics are produced by major firms who have large research and development budgets, which in the development formulas for attacking the resistant bacteria harder than the over-counter antibiotics. Notwithstanding the increased use of generics by patients, many hospitals and clinics prefer branded antibiotics; particularly when treating serious infections. Forces like strict government regulation policies, quality while purchasing the products and promotional strategies by the big pharmaceutical companies also ensure that the branded antibiotics continue to have a large market share in the market.
Antibiotics Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- North America had the highest market share in the antibiotics market in 2023 as a result of effective health care systems, high expenditure on health care, and high outspread of bacterial infections. Other highly developed industries include pharmaceuticals and there is already a good a legal framework in place regarding bacterial antibiotic innovations. North America market share for global antibiotic consumption was about 35% in the year 2023. Higher rates of hospital acquired diseases, rise in concern over antibiotic use and containments and top pharma companies located in the region are some of the factors that supports the region. Furthermore, continuous research and development of antibiotic to fight against bacteria resistant to antibiotics to continue to drive North America antibiotic market during the forecast period.
Active Key Players in the Antibiotics Market
- Abbott Laboratories (United States)
- Astellas Pharma (Japan)
- Bayer (Germany)
- Daiichi Sankyo (Japan)
- Eli Lilly (United States)
- GlaxoSmithKline (United Kingdom)
- Johnson & Johnson (United States)
- Lupin (India)
- Merck & Co. (United States)
- Novartis (Switzerland)
- Pfizer (United States)
- Roche (Switzerland)
- Sanofi (France)
- Sun Pharmaceutical (India)
- Takeda Pharmaceutical (Japan), Other key Players.
|
Global Antibiotics Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 50.8 Billion |
|
Forecast Period 2024-32 CAGR: |
4.1% |
Market Size in 2032: |
USD 72.9 Billion |
|
Segments Covered: |
By Drug Class |
|
|
|
By Type |
|
||
|
By Action Mechanism |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Antibiotics Market by Drug Class (2018-2032)
4.1 Antibiotics Market Snapshot and Growth Engine
4.2 Market Overview
4.3 Cephalosporin
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
4.3.3 Key Market Trends, Growth Factors, and Opportunities
4.3.4 Geographic Segmentation Analysis
4.4 Penicillin
4.5 Fluoroquinolone
4.6 Macrolides
4.7 Carbapenems
4.8 Aminoglycosides
4.9 Sulfonamides
4.10 7-ACA
4.11 Others
Chapter 5: Antibiotics Market by Type (2018-2032)
5.1 Antibiotics Market Snapshot and Growth Engine
5.2 Market Overview
5.3 Branded Antibiotics
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
5.3.3 Key Market Trends, Growth Factors, and Opportunities
5.3.4 Geographic Segmentation Analysis
5.4 Generic Antibiotics
Chapter 6: Antibiotics Market by Action Mechanism (2018-2032)
6.1 Antibiotics Market Snapshot and Growth Engine
6.2 Market Overview
6.3 Cell Wall Synthesis Inhibitors
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
6.3.3 Key Market Trends, Growth Factors, and Opportunities
6.3.4 Geographic Segmentation Analysis
6.4 Protein Synthesis Inhibitors
6.5 DNA Synthesis Inhibitors
6.6 RNA Synthesis Inhibitors
6.7 Mycolic Acid Inhibitors
6.8 Others
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Antibiotics Market Share by Manufacturer (2024)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 ABBOTT LABORATORIES (UNITED STATES)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 ASTELLAS PHARMA (JAPAN)
7.4 BAYER (GERMANY)
7.5 DAIICHI SANKYO (JAPAN)
7.6 ELI LILLY (UNITED STATES)
7.7 GLAXOSMITHKLINE (UNITED KINGDOM)
7.8 JOHNSON & JOHNSON (UNITED STATES)
7.9 LUPIN (INDIA)
7.10 MERCK & CO. (UNITED STATES)
7.11 NOVARTIS (SWITZERLAND)
7.12 PFIZER (UNITED STATES)
7.13 ROCHE (SWITZERLAND)
7.14 SANOFI (FRANCE)
7.15 SUN PHARMACEUTICAL (INDIA)
7.16 TAKEDA PHARMACEUTICAL (JAPAN)
7.17 OTHER KEY PLAYERS
Chapter 8: Global Antibiotics Market By Region
8.1 Overview
8.2. North America Antibiotics Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size by Drug Class
8.2.4.1 Cephalosporin
8.2.4.2 Penicillin
8.2.4.3 Fluoroquinolone
8.2.4.4 Macrolides
8.2.4.5 Carbapenems
8.2.4.6 Aminoglycosides
8.2.4.7 Sulfonamides
8.2.4.8 7-ACA
8.2.4.9 Others
8.2.5 Historic and Forecasted Market Size by Type
8.2.5.1 Branded Antibiotics
8.2.5.2 Generic Antibiotics
8.2.6 Historic and Forecasted Market Size by Action Mechanism
8.2.6.1 Cell Wall Synthesis Inhibitors
8.2.6.2 Protein Synthesis Inhibitors
8.2.6.3 DNA Synthesis Inhibitors
8.2.6.4 RNA Synthesis Inhibitors
8.2.6.5 Mycolic Acid Inhibitors
8.2.6.6 Others
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Antibiotics Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size by Drug Class
8.3.4.1 Cephalosporin
8.3.4.2 Penicillin
8.3.4.3 Fluoroquinolone
8.3.4.4 Macrolides
8.3.4.5 Carbapenems
8.3.4.6 Aminoglycosides
8.3.4.7 Sulfonamides
8.3.4.8 7-ACA
8.3.4.9 Others
8.3.5 Historic and Forecasted Market Size by Type
8.3.5.1 Branded Antibiotics
8.3.5.2 Generic Antibiotics
8.3.6 Historic and Forecasted Market Size by Action Mechanism
8.3.6.1 Cell Wall Synthesis Inhibitors
8.3.6.2 Protein Synthesis Inhibitors
8.3.6.3 DNA Synthesis Inhibitors
8.3.6.4 RNA Synthesis Inhibitors
8.3.6.5 Mycolic Acid Inhibitors
8.3.6.6 Others
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Antibiotics Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size by Drug Class
8.4.4.1 Cephalosporin
8.4.4.2 Penicillin
8.4.4.3 Fluoroquinolone
8.4.4.4 Macrolides
8.4.4.5 Carbapenems
8.4.4.6 Aminoglycosides
8.4.4.7 Sulfonamides
8.4.4.8 7-ACA
8.4.4.9 Others
8.4.5 Historic and Forecasted Market Size by Type
8.4.5.1 Branded Antibiotics
8.4.5.2 Generic Antibiotics
8.4.6 Historic and Forecasted Market Size by Action Mechanism
8.4.6.1 Cell Wall Synthesis Inhibitors
8.4.6.2 Protein Synthesis Inhibitors
8.4.6.3 DNA Synthesis Inhibitors
8.4.6.4 RNA Synthesis Inhibitors
8.4.6.5 Mycolic Acid Inhibitors
8.4.6.6 Others
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Antibiotics Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size by Drug Class
8.5.4.1 Cephalosporin
8.5.4.2 Penicillin
8.5.4.3 Fluoroquinolone
8.5.4.4 Macrolides
8.5.4.5 Carbapenems
8.5.4.6 Aminoglycosides
8.5.4.7 Sulfonamides
8.5.4.8 7-ACA
8.5.4.9 Others
8.5.5 Historic and Forecasted Market Size by Type
8.5.5.1 Branded Antibiotics
8.5.5.2 Generic Antibiotics
8.5.6 Historic and Forecasted Market Size by Action Mechanism
8.5.6.1 Cell Wall Synthesis Inhibitors
8.5.6.2 Protein Synthesis Inhibitors
8.5.6.3 DNA Synthesis Inhibitors
8.5.6.4 RNA Synthesis Inhibitors
8.5.6.5 Mycolic Acid Inhibitors
8.5.6.6 Others
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Antibiotics Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size by Drug Class
8.6.4.1 Cephalosporin
8.6.4.2 Penicillin
8.6.4.3 Fluoroquinolone
8.6.4.4 Macrolides
8.6.4.5 Carbapenems
8.6.4.6 Aminoglycosides
8.6.4.7 Sulfonamides
8.6.4.8 7-ACA
8.6.4.9 Others
8.6.5 Historic and Forecasted Market Size by Type
8.6.5.1 Branded Antibiotics
8.6.5.2 Generic Antibiotics
8.6.6 Historic and Forecasted Market Size by Action Mechanism
8.6.6.1 Cell Wall Synthesis Inhibitors
8.6.6.2 Protein Synthesis Inhibitors
8.6.6.3 DNA Synthesis Inhibitors
8.6.6.4 RNA Synthesis Inhibitors
8.6.6.5 Mycolic Acid Inhibitors
8.6.6.6 Others
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Antibiotics Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size by Drug Class
8.7.4.1 Cephalosporin
8.7.4.2 Penicillin
8.7.4.3 Fluoroquinolone
8.7.4.4 Macrolides
8.7.4.5 Carbapenems
8.7.4.6 Aminoglycosides
8.7.4.7 Sulfonamides
8.7.4.8 7-ACA
8.7.4.9 Others
8.7.5 Historic and Forecasted Market Size by Type
8.7.5.1 Branded Antibiotics
8.7.5.2 Generic Antibiotics
8.7.6 Historic and Forecasted Market Size by Action Mechanism
8.7.6.1 Cell Wall Synthesis Inhibitors
8.7.6.2 Protein Synthesis Inhibitors
8.7.6.3 DNA Synthesis Inhibitors
8.7.6.4 RNA Synthesis Inhibitors
8.7.6.5 Mycolic Acid Inhibitors
8.7.6.6 Others
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Antibiotics Market by Drug Class (2018-2032)
4.1 Antibiotics Market Snapshot and Growth Engine
4.2 Market Overview
4.3 Cephalosporin
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
4.3.3 Key Market Trends, Growth Factors, and Opportunities
4.3.4 Geographic Segmentation Analysis
4.4 Penicillin
4.5 Fluoroquinolone
4.6 Macrolides
4.7 Carbapenems
4.8 Aminoglycosides
4.9 Sulfonamides
4.10 7-ACA
4.11 Others
Chapter 5: Antibiotics Market by Type (2018-2032)
5.1 Antibiotics Market Snapshot and Growth Engine
5.2 Market Overview
5.3 Branded Antibiotics
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
5.3.3 Key Market Trends, Growth Factors, and Opportunities
5.3.4 Geographic Segmentation Analysis
5.4 Generic Antibiotics
Chapter 6: Antibiotics Market by Action Mechanism (2018-2032)
6.1 Antibiotics Market Snapshot and Growth Engine
6.2 Market Overview
6.3 Cell Wall Synthesis Inhibitors
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
6.3.3 Key Market Trends, Growth Factors, and Opportunities
6.3.4 Geographic Segmentation Analysis
6.4 Protein Synthesis Inhibitors
6.5 DNA Synthesis Inhibitors
6.6 RNA Synthesis Inhibitors
6.7 Mycolic Acid Inhibitors
6.8 Others
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Antibiotics Market Share by Manufacturer (2024)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 ABBOTT LABORATORIES (UNITED STATES)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 ASTELLAS PHARMA (JAPAN)
7.4 BAYER (GERMANY)
7.5 DAIICHI SANKYO (JAPAN)
7.6 ELI LILLY (UNITED STATES)
7.7 GLAXOSMITHKLINE (UNITED KINGDOM)
7.8 JOHNSON & JOHNSON (UNITED STATES)
7.9 LUPIN (INDIA)
7.10 MERCK & CO. (UNITED STATES)
7.11 NOVARTIS (SWITZERLAND)
7.12 PFIZER (UNITED STATES)
7.13 ROCHE (SWITZERLAND)
7.14 SANOFI (FRANCE)
7.15 SUN PHARMACEUTICAL (INDIA)
7.16 TAKEDA PHARMACEUTICAL (JAPAN)
7.17 OTHER KEY PLAYERS
Chapter 8: Global Antibiotics Market By Region
8.1 Overview
8.2. North America Antibiotics Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size by Drug Class
8.2.4.1 Cephalosporin
8.2.4.2 Penicillin
8.2.4.3 Fluoroquinolone
8.2.4.4 Macrolides
8.2.4.5 Carbapenems
8.2.4.6 Aminoglycosides
8.2.4.7 Sulfonamides
8.2.4.8 7-ACA
8.2.4.9 Others
8.2.5 Historic and Forecasted Market Size by Type
8.2.5.1 Branded Antibiotics
8.2.5.2 Generic Antibiotics
8.2.6 Historic and Forecasted Market Size by Action Mechanism
8.2.6.1 Cell Wall Synthesis Inhibitors
8.2.6.2 Protein Synthesis Inhibitors
8.2.6.3 DNA Synthesis Inhibitors
8.2.6.4 RNA Synthesis Inhibitors
8.2.6.5 Mycolic Acid Inhibitors
8.2.6.6 Others
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Antibiotics Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size by Drug Class
8.3.4.1 Cephalosporin
8.3.4.2 Penicillin
8.3.4.3 Fluoroquinolone
8.3.4.4 Macrolides
8.3.4.5 Carbapenems
8.3.4.6 Aminoglycosides
8.3.4.7 Sulfonamides
8.3.4.8 7-ACA
8.3.4.9 Others
8.3.5 Historic and Forecasted Market Size by Type
8.3.5.1 Branded Antibiotics
8.3.5.2 Generic Antibiotics
8.3.6 Historic and Forecasted Market Size by Action Mechanism
8.3.6.1 Cell Wall Synthesis Inhibitors
8.3.6.2 Protein Synthesis Inhibitors
8.3.6.3 DNA Synthesis Inhibitors
8.3.6.4 RNA Synthesis Inhibitors
8.3.6.5 Mycolic Acid Inhibitors
8.3.6.6 Others
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Antibiotics Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size by Drug Class
8.4.4.1 Cephalosporin
8.4.4.2 Penicillin
8.4.4.3 Fluoroquinolone
8.4.4.4 Macrolides
8.4.4.5 Carbapenems
8.4.4.6 Aminoglycosides
8.4.4.7 Sulfonamides
8.4.4.8 7-ACA
8.4.4.9 Others
8.4.5 Historic and Forecasted Market Size by Type
8.4.5.1 Branded Antibiotics
8.4.5.2 Generic Antibiotics
8.4.6 Historic and Forecasted Market Size by Action Mechanism
8.4.6.1 Cell Wall Synthesis Inhibitors
8.4.6.2 Protein Synthesis Inhibitors
8.4.6.3 DNA Synthesis Inhibitors
8.4.6.4 RNA Synthesis Inhibitors
8.4.6.5 Mycolic Acid Inhibitors
8.4.6.6 Others
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Antibiotics Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size by Drug Class
8.5.4.1 Cephalosporin
8.5.4.2 Penicillin
8.5.4.3 Fluoroquinolone
8.5.4.4 Macrolides
8.5.4.5 Carbapenems
8.5.4.6 Aminoglycosides
8.5.4.7 Sulfonamides
8.5.4.8 7-ACA
8.5.4.9 Others
8.5.5 Historic and Forecasted Market Size by Type
8.5.5.1 Branded Antibiotics
8.5.5.2 Generic Antibiotics
8.5.6 Historic and Forecasted Market Size by Action Mechanism
8.5.6.1 Cell Wall Synthesis Inhibitors
8.5.6.2 Protein Synthesis Inhibitors
8.5.6.3 DNA Synthesis Inhibitors
8.5.6.4 RNA Synthesis Inhibitors
8.5.6.5 Mycolic Acid Inhibitors
8.5.6.6 Others
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Antibiotics Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size by Drug Class
8.6.4.1 Cephalosporin
8.6.4.2 Penicillin
8.6.4.3 Fluoroquinolone
8.6.4.4 Macrolides
8.6.4.5 Carbapenems
8.6.4.6 Aminoglycosides
8.6.4.7 Sulfonamides
8.6.4.8 7-ACA
8.6.4.9 Others
8.6.5 Historic and Forecasted Market Size by Type
8.6.5.1 Branded Antibiotics
8.6.5.2 Generic Antibiotics
8.6.6 Historic and Forecasted Market Size by Action Mechanism
8.6.6.1 Cell Wall Synthesis Inhibitors
8.6.6.2 Protein Synthesis Inhibitors
8.6.6.3 DNA Synthesis Inhibitors
8.6.6.4 RNA Synthesis Inhibitors
8.6.6.5 Mycolic Acid Inhibitors
8.6.6.6 Others
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Antibiotics Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size by Drug Class
8.7.4.1 Cephalosporin
8.7.4.2 Penicillin
8.7.4.3 Fluoroquinolone
8.7.4.4 Macrolides
8.7.4.5 Carbapenems
8.7.4.6 Aminoglycosides
8.7.4.7 Sulfonamides
8.7.4.8 7-ACA
8.7.4.9 Others
8.7.5 Historic and Forecasted Market Size by Type
8.7.5.1 Branded Antibiotics
8.7.5.2 Generic Antibiotics
8.7.6 Historic and Forecasted Market Size by Action Mechanism
8.7.6.1 Cell Wall Synthesis Inhibitors
8.7.6.2 Protein Synthesis Inhibitors
8.7.6.3 DNA Synthesis Inhibitors
8.7.6.4 RNA Synthesis Inhibitors
8.7.6.5 Mycolic Acid Inhibitors
8.7.6.6 Others
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
|
Global Antibiotics Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 50.8 Billion |
|
Forecast Period 2024-32 CAGR: |
4.1% |
Market Size in 2032: |
USD 72.9 Billion |
|
Segments Covered: |
By Drug Class |
|
|
|
By Type |
|
||
|
By Action Mechanism |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Frequently Asked Questions :
What would be the forecast period in the Antibiotics Market research report?
The forecast period in the Antibiotics Market research report is 2024-2032.
Who are the key players in the Antibiotics Market?
Pfizer, GlaxoSmithKline, Sanofi, Merck & Co., and Novartis and Other Major Players.
What are the segments of the Antibiotics Market?
The Antibiotics Market is segmented into Drug Class, Type, Action Mechanism and region. By Drug Class, the market is categorized into Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenems, Aminoglycosides, Sulfonamides, 7-ACA, Others. By Type, the market is categorized into Branded Antibiotics, Generic Antibiotics. By Action Mechanism, the market is categorized into Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, Mycolic Acid Inhibitors, Others. By region, it is analyzed across North America (U.S.; Canada; Mexico), Eastern Europe (Bulgaria; The Czech Republic; Hungary; Poland; Romania; Rest of Eastern Europe), Western Europe (Germany; UK; France; Netherlands; Italy; Russia; Spain; Rest of Western Europe), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).
What is the Antibiotics Market?
The antibiotics market is defined as the worldwide demand for medicines intended to combat bacterial infections and either eliminate them or prevent their development. Antibiotics are important in managing most infections such as respiratory, urinary, skin, and gastrointestinal infections to mention but a few. This market included branded and generic antibiotics of penicillin, cephalosporin, macrolides, and tetracyclines therapeutic classes. The global need for better antibiotic treatment reaches higher levels when bacterial infections increase, and healthcare facilities improve concurrently.
How big is the Antibiotics Market?
Antibiotics Market Size Was Valued at USD 50.8 Billion in 2023, and is Projected to Reach USD 72.9 Billion by 2032, Growing at a CAGR of 4.1% From 2024-2032.
